GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Net Change in Cash

Audeo Oncology (Audeo Oncology) Net Change in Cash : $4.46 Mil (TTM As of Sep. 2012)


View and export this data going back to . Start your Free Trial

What is Audeo Oncology Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Audeo Oncology's Net Change in Cash for the three months ended in Sep. 2012 was $-3.30 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2012 was $4.46 Mil.

Audeo Oncology Net Change in Cash Historical Data

The historical data trend for Audeo Oncology's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology Net Change in Cash Chart

Audeo Oncology Annual Data
Trend Jun10 Jun11 Jun12
Net Change in Cash
-0.12 0.11 7.60

Audeo Oncology Quarterly Data
Jun11 Mar12 Jun12 Sep12
Net Change in Cash 0.14 0.04 7.72 -3.30

Audeo Oncology Net Change in Cash Calculation

Audeo Oncology's Net Change in Cash for the fiscal year that ended in Jun. 2012 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=7.63+-0.027+0+0
=7.60

Audeo Oncology's Net Change in Cash for the quarter that ended in Sep. 2012

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-3.285+-0.016+0+0
=-3.30

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Audeo Oncology Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Net Change in Cash
Comparable Companies
BOM:524572 BOM:531099 BOM:524322 BOM:530665 BOM:524661 BOM:526075 BUD:NUTEX BOM:531569 ENZB BOM:531762 BOM:524400 TSXV:AHS BOM:524752 BOM:531210 BOM:523620 BOM:530207 FRA:P8H1 BOM:531173 FRA:7BNB FRA:NTP
Traded in Other Exchanges
N/A
Address
Website
http://www.audeooncology.com
Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.